QNRX

Quoin Pharmaceuticals Ltd. (QNRX) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Quoin Pharmaceuticals Ltd. is a late-stage clinical specialty pharmaceutical company focused on rare and orphan diseases. The Company has no commercialized products and generates no revenue. Its lead product, QRX003, is in pivotal registrational clinical testing for Netherton Syndrome. The Company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $1.19 million (31%) compared to Q1 2025, driven primarily by higher operating expenses.
• Operating Expenses: Total operating expenses rose by $1.17 million.
  • Research & Development (R&D): Increased by $1.06 million (45%) to $3.43 million, attributed to increased external clinical development expenditures ($767k), higher payroll ($192k), and stock-based compensation ($101k).
  • General & Administrative (G&A): Increased by $114k (7%) to $1.70 million, due to higher commercial, payroll, and consulting costs, partially offset by reduced board fees.
• Liquidity Position: Cash and cash equivalents decreased by approximately $694k during the quarter. Investments decreased by $4.0 million due to redemptions to fund operations.
• Capital Structure: The Company raised approximately $206k in net proceeds from the exercise of pre-funded warrants and warrants in January 2026. Outstanding ordinary shares increased from 52.4 million to 68.6 million.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least one year from the filing date. The Company has an accumulated deficit of approximately $76 million and requires additional funding to sustain operations.
• Regulatory Milestones:
  • Received FDA Fast Track Designation for QRX003 (Netherton Syndrome) in March 2026.
  • FDA indicated a single Phase 3 study may be sufficient for US approval and expressed openness to an alternate study design without a traditional placebo control.
  • Filed for Breakthrough Medicine Designation in Saudi Arabia and Orphan Drug Designation in Japan.
• Pipeline Updates: QRX003 is being tested in pediatric patients for Netherton Syndrome and Peeling Skin Syndrome. The Company plans to submit an IND for QRX009 (topical rapamycin) for additional indications in Q3 2026.
• Financing Needs: The Company must raise additional capital through equity, debt, or strategic partnerships. Failure to secure funding could force the delay or termination of development programs.
• Commitments: The Company has significant future payment obligations, including a potential $5 million milestone payment to Skinvisible upon regulatory approval and ongoing clinical trial costs with Therapeutics Inc. and Evestia Clinical Limited.

Investor Verification Checklist

• Cash Runway: Verify the specific duration of the current cash balance ($3.1M cash + $10.9M investments) against the burn rate of ~$5M per quarter to assess immediate liquidity risk.
• Financing Terms: Review the terms of the October 2025 private placement and any restrictions on future capital raises mentioned in the filing.
• Clinical Trial Costs: Confirm the remaining estimated costs for the QRX003 pivotal trials (approx. $3.6M remaining as of late 2024) and the new UK/European study ($800k).
• Related Party Debt: Note the $2.17 million in accrued salaries and compensation due to officers/founders, of which $1.57 million is classified as long-term.
• Warrant Dilution: Assess the impact of 9.76 million outstanding warrants (weighted average exercise price $10.97) on future dilution if exercised.